Grant-in-Aid for Scientific Research (C)
Purpose of this study was (i) to establish ELISA system to detect serum anti-RalA antibodies, anti-Sui1 antibodies, and anti-NY-ESO-1 antibodies, (ii) to evaluate positive rate of serum anti-RalA, Sui1 and NY-ESO-1 antibodies in 172 patients with esophageal squamous cell carcinoma. Using a cut-off value of mean +3SD of serum each auto-antibody levels of healthy controls, positive rate of patients with esophageal squamous cell carcinoma was 14% for RalA antibodies, 8% for Sui1 antibodies and 32% for NY-ESO-1 antibodies. Although tumor stages were associated with presence of anti-NY-ESO-1 antibodies, no significant associations were observed between clinicopathological factors and anti-RalA antibodies nor anti-Sui1 antibodies.
Gratis J Biomed Sci,
Journal of thoracic oncology
Attribution of KAKENHI